FDA Removes REMS Requirements for CAR T Cell Therapies, Boosting Patient Access
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for all currently approved BCMA- and CD19-directed …
FDA Removes REMS Requirements for CAR T Cell Therapies, Boosting Patient Access Read More